Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3012% above fair value

$9.37+0.06 (+0.64%)

Close on Nov 13, 2026Market cap $799.39MP/E –Yield –

Monte Rosa Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Monte Rosa Therapeutics's EV/EBITDA was 103.0× on Jan 30, 2026.

Period	Period end	Value	Change (pts)
2026	Jan 30, 2026	103.0×	+35.1
2025	Dec 31, 2025	67.9×	–

Parsed from the XBRL in Monte Rosa Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GLUE.

Revenue growth-61.3% · median -25.0%

Operating margin-214.5% · median -315.9%

Net margin-186.2% · median -341.8%

Advertisement
300 × 250

See a number that looks wrong?